Latest News

  • Carlene Knight would love to do things that most people take for granted, such as read books, drive a car, ride a bike, gaze at animals in a zoo and watch movies. She also longs to see expressions on people’s faces. “To be able to see my granddaughter especially —...
  • NEWARK, Calif. – CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that seasoned biopharma executive Lewis Stuart has joined the company as Chief Commercial Officer. Mr. Stuart brings more than 25 years of...
  • WORCESTER, Mass. – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s...

Videos

Rare disease spotlight

Twitter

A mathematical model developed by our Mathematics in Medicine program in partnership with @MDAndersonnews quantifies tumor sensitivity to help predict responses to immunotherapy in #cancer patients.

Our #onePTC team is observing #PKUAwarenessMonth. #Phenylketonuria (#PKU) is a #raredisease that, untreated, can cause intellectual disabilities, #seizures and more. We are investigating PTC923, which has the potential to address these symptoms in a broad range of PKU patients.

Abeona is proud to share data from multiple programs at this year’s ASGCT. Visit ePoster #367 to learn about our preclinical work in Stargardt, #830, #807 for news on process development, and on May 14th, join us for oral presentations for our Transpher A and Transpher B studies.

I push industry partners to do better. Often with little results but when I’m heard and the result could mean more access to treatment it is worth the sore arms from pulling out the soapbox! #TakeTheWins #PatientInclusion

Load More...